Insys agrees to pay $4.45M to settle opioid marketing suit
Illinois Attorney General Lisa Madigan today announced a $4.45M settlement with the pharmaceutical company Insys Therapeutics for deceptively marketing and selling a highly addictive opioid drug for an array of treatments that were not approved by the Food And Drug Administration. The settlement resolves Madigan's 2016 lawsuit against Insys for its sale of Subsys, which is significantly more powerful than morphine and intended exclusively for the treatment of breakthrough cancer pain. Madigan alleged Insys deceptively promoted and sold Subsys to treat a wide variety of pain, such as back and neck pain, even though the drug was not approved for those uses. "Insys pushed a highly addictive opioid in complete disregard for patients' health to increase company profits," Madigan said. "It's unethical, greedy behavior by companies like Insys that is responsible for creating the opioid epidemic and resulting overdose deaths in our state." Madigan will use the $4.45M from the settlement to address the significant increase in opioid abuse in communities throughout Illinois.